Skip to content

Svennilson Peter

Follow

13F filer, CIK 1606074, SAN FRANCISCO, CA

Svennilson Peter reported $789,930,000 across 6 holdings for the quarter ended 2020-03-31, in a 13F-HR filed 2020-05-07.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001606074-20-000005

Period
2020-03-31
Reported value
$790M
Holdings
6
Top 10 weight
100%
New
1
Sold out
0

Stakes and trades reported after 2020-03-31

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
    Accepted , ingested
  • TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RVMDnew+7,977,384$175M
NGM BIOPHARMACEUTICALS INCadded+902,315$11.1M
CONSTELLATION PHARMACEUTICALadded+41,674$1.31M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q1 2020

Share positions as resolved from 13F-HR 0001606074-20-000005, largest first. % of portfolio is the value over $789,930,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: 15,694,091 shares; 2019Q3: 16,166,907 shares; 2019Q4: 16,420,829 shares; 2020Q1: 17,323,144 shares 17,323,144$214M27.04%+902,315
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 4,677,938 shares; 2019Q1: 4,677,939 shares; 2019Q2: 4,677,939 shares; 2019Q3: 6,009,702 shares; 2019Q4: 6,009,702 shares; 2020Q1: 6,051,376 shares 6,051,376$190M24.08%+41,674
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: not reported; 2019Q3: not reported; 2019Q4: not reported; 2020Q1: 7,977,384 shares 7,977,384$175M22.13%newTimeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: not reported; 2019Q3: not reported; 2019Q4: 6,777,151 shares; 2020Q1: 6,777,151 shares 6,777,151$144M18.25%0
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,540,850 shares; 2019Q1: 3,540,850 shares; 2019Q2: 3,540,850 shares; 2019Q3: 3,540,850 shares; 2019Q4: 3,540,850 shares; 2020Q1: 3,540,850 shares 3,540,850$49.1M6.22%0Timeline
GRITSTONE BIO INCGRITSTONE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,102,934 shares; 2019Q1: 3,102,934 shares; 2019Q2: 3,102,934 shares; 2019Q3: 3,102,934 shares; 2019Q4: 3,102,934 shares; 2020Q1: 3,102,934 shares 3,102,934$18.1M2.29%0

How Q1 2020 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001606074-20-000005 base2020-05-07acceptance time not in the bulk data set